Shield Therapeutics (LSE:STX) Price-to-Tangible-Book : 0.91 (As of May. 04, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Price-to-Tangible-Book?

As of today (2024-05-04), Shield Therapeutics's share price is £0.0155. Shield Therapeutics's Tangible Book per Share of Jun. 2023 for the quarter that ended in Jun. 2023 was £0.02. Hence, Shield Therapeutics's Price to Tangible Book Ratio of today is 0.91.

The historical rank and industry rank for Shield Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

LSE:STX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.68 Med: 9.17 Max: 91.52
Current: 0.78

During the past 9 years, Shield Therapeutics's highest Price to Tangible Book Ratio was 91.52. The lowest was 0.68. And the median was 9.17.

LSE:STX's Price-to-Tangible-Book is ranked better than
89.46% of 873 companies
in the Drug Manufacturers industry
Industry Median: 2.35 vs LSE:STX: 0.78

A closely related ratio is called PB Ratio. As of today, Shield Therapeutics's share price is £0.0155. Shield Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2023 was £0.04. Hence, Shield Therapeutics's P/B Ratio of today is 0.41.

Shield Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Shield Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Price-to-Tangible-Book Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Tangible-Book

Get a 7-Day Free Trial

3.75

91.52

24.67

6.97

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Price-to-Tangible-Book	Get a 7-Day Free Trial													4.47	6.97	2.91	-	3.97

Competitive Comparison of Shield Therapeutics's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Price-to-Tangible-Book falls into.

Shield Therapeutics Price-to-Tangible-Book Calculation

Shield Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2023 )
	=	0.0155	/	0.017
	=	0.91

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Shield Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.